Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Explore clinical trials studying Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Study availability and eligibility vary by location and protocol.

3 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) trial results

Completed

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UCLA Santa Monica, California, United States
View all 72 locations
View Trial Details
Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT03992339

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Anhui Province Cancer Hospital Hefei, Anhui, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Chongqing Universtity Cancer Hospital Chongqing, Chongqing Municipality, China
View all 18 locations
View Trial Details

Related conditions